Targeting the HER/EGFR/ErbB family to prevent breast cancer. - Wikidata - awgldk - TriplyDB

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

http://www.wikidata.org/entity/Q35208654

about

PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies Assay of lapatinib in murine models of cigarette smoke carcinogenesis.CDK7-dependent transcriptional addiction in triple-negative breast cancer.RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.Automated analysis of immunohistochemistry images identifies candidate location biomarkers for cancers.RTK/ERK pathway under natural selection associated with prostate cancer.In Utero exposure to low-dose alcohol induces reprogramming of mammary development and tumor risk in MMTV-erbB-2 transgenic mice Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy.miR-sc8 Inhibits Schwann Cell Proliferation and Migration by Targeting Egfr.Salivary Protein Profiles among HER2/neu-Receptor-Positive and -Negative Breast Cancer Patients: Support for Using Salivary Protein Profiles for Modeling Breast Cancer Progression.Animal models for exploring the pharmacokinetics of breast cancer therapies HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.Role of ErbB Receptors in Cancer Cell Migration and Invasion Endocrine resistance in breast cancer--An overview and update.Preclinical HER-2 Vaccines: From Rodent to Human HER-2 HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction.Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer Clinical applications of mouse models for breast cancer engaging HER2/neu.N-Methyl-N-nitrosourea as a mammary carcinogenic agent.Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway.Network-based pathway enrichment analysis with incomplete network information.Breast reconstruction with autologous fat graft; does platelet-rich plasma affect patient's survival?The GDNF Family: A Role in Cancer?Targeted Therapies Against Growth Factor Signaling in Breast Cancer.Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma.Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action.Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.An intermittent approach for cancer chemoprevention.Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer.Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth

P2860

Q24323230-9B7982C5-24D5-425E-B712-965A38DBC35B Q34158454-4EB8C64A-7C7A-438B-9D05-6442F05C1B3C Q34260243-BC54E1C6-9A8B-46B6-A424-0A8B5522CB9B Q34495729-3343C5FD-CA98-4014-9AEB-EED8ACA9B6A8 Q34510318-74CC9D6B-D67B-4C14-AF55-C973A1267413 Q34793009-E34E5EA9-9AA0-41C5-A7C2-909A5E9ADFD4 Q35040853-E0A9B02D-AD01-4F71-8D3C-1BAE9BCDD3CC Q35585536-54AE0C47-D9D0-48D9-AFF8-17991D28FC69 Q35663802-935DAA66-8693-4748-90AE-D9F4D680B661 Q35682599-92C53130-F420-4667-AE4B-88553F44D14C Q35851983-1960038E-687C-4398-9EC0-E304E538C4DB Q35873039-7C1E7AC4-AA72-4332-B732-7FAC4E90D499 Q35909258-F29DA49C-6A0B-4B19-A370-022786A27E59 Q36093956-77607D66-EABE-4F87-A456-360F9E6D51C0 Q36106546-41A0F66A-73B3-4A1F-89AB-F722F600C145 Q36114852-73622930-9FB0-40FB-A126-E21714BD5312 Q36203244-C73374E3-9129-49A5-85EB-E6F06536BC95 Q36311027-EE7CBB8D-F157-4DE8-90FE-C310C1C7F709 Q36386322-CFF559F9-7906-4579-B262-E1B2E4B8C6EF Q36914661-647F1B12-413B-49A3-AF1C-FBDE79C18D24 Q36957145-79BCD49D-863A-43C3-8F19-6AF7E7980679 Q37017096-F9F8FE45-E609-4137-9F5A-B2FF64DC0F99 Q37125328-7CD432FE-E3D9-48B8-A74F-AB618FFA33DB Q37607675-A2D58A96-6813-4346-B577-2C589749EC03 Q38589651-8B29B5B3-21C8-47B4-8D2B-77D494146F85 Q38940200-F686B826-E124-4A29-83CB-223E12B4ACF6 Q39016174-ED74CC89-E314-480D-9FF3-0992C1999390 Q39644743-857DEDB9-9C2D-4241-9E3D-00D78E36ABF3 Q41891665-8F26BD74-051C-4D08-A825-E23C45E6B08D Q47137356-B990E316-3494-4BA6-B6B5-BECDE0ACAC76 Q47559665-FA79F33C-FE2D-48BC-B637-C393445070CD Q48026385-28D1FA2F-83C5-4FBA-A588-88924EEA1C84 Q49378719-3497036C-BAA6-4EFD-900F-A14469109AE8 Q50592584-99F0EC4A-15F4-4B2A-98DE-86239A5A0434 Q51662524-219BF9D3-BECF-4EC7-8A37-19E1FC513065 Q52658477-AD7EBA48-99DF-4848-AEBF-51D584BC5BFC Q58728275-45BD01A6-4840-4AC5-A04C-67B1393D2778

P2860

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

http://www.wikidata.org/entity/Q35208654

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

@ast

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

@en

type

label

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

@ast

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

@en

prefLabel

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

@ast

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

@en

P1433

Q35208654-B603F15C-56AF-4B45-9226-37E00C75D1BD

P1476

Q35208654-DB1E38DF-A297-4A63-B5B7-851220657C1C

P2093

Q35208654-53CA3E91-5B79-4DAB-A63E-4155FE7E68A6

P2860

Q35208654-04701CF0-3A16-47C7-A952-EE281D37FDAE

Q35208654-1B6D4054-D37A-4D1A-91C0-808EF3AE3B0A

Q35208654-20659221-95FE-4B94-9BDA-E639C1A6D95B

Q35208654-26219CB3-170F-4CDD-9844-1EAE96678AD3

Q35208654-290B9539-FDCB-473C-A6EE-7881AE9A7910

Q35208654-2FED21E0-678A-4FE6-B4F2-BA16C3198224

Q35208654-3459582B-437F-46A7-AA94-40EE01636AE4

Q35208654-3D3CB8F6-7237-4AC0-88AA-888AB7D84928

Q35208654-447268E9-4B1E-4E6B-A5B9-293D7BE38584

Q35208654-59FD5DDA-7ED0-4D04-8426-51287F063AE6

P304

Q35208654-5F48D357-3E4D-4A32-89B9-44A6A2FCABC5

P31

Q35208654-13C5C163-E6BD-497C-BADE-D8CFB789A291

P356

Q35208654-E3BBA969-D865-43DC-8C5A-F9AABD2C0A71

P433

Q35208654-AA05BB51-310C-40C9-9673-E9CC0F59BF7D

P478

Q35208654-AF877D25-55E8-494E-9D1D-13553CDEA118

P50

Q35208654-93A279A1-62B8-4548-823A-837CF3668425

P577

Q35208654-769F4069-4B91-446B-A998-88B1809CBE97

P5875

Q35208654-9B9D2852-3389-465C-9738-C5265295E034

P698

Q35208654-6F825CC7-84A0-49B2-995B-EA62C877F5FD

P932

Q35208654-E1E83A2A-3076-4AD9-8290-49AD3A3F82F4

P356

1940-6207.CAPR-11-0334

P1433

Cancer Prevention Research

P1476

Targeting the HER/EGFR/ErbB family to prevent breast cancer

@en

P2093

Powel H Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

P304

1149-1157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-11-0334

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51547434

http://www.w3.org/2001/XMLSchema#string

P698

21816844

http://www.w3.org/2001/XMLSchema#string

P932

3171200

http://www.w3.org/2001/XMLSchema#string